TLX
Telix Pharmaceuticals Limited NASDAQ$11.15
Mkt Cap $3.8B
52w Low $6.28
38.7% of range
52w High $18.87
50d MA $8.99
200d MA $9.58
P/E (TTM)
-356.3x
EV/EBITDA
54.7x
P/B
6.1x
Debt/Equity
1.3x
ROE
—
P/FCF
-45.8x
RSI (14)
—
ATR (14)
—
Beta
0.61
50d MA
$8.99
200d MA
$9.58
Avg Volume
261.8K
About
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its …
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 19, 2026 | AMC | 0.03 | -0.01 | -135.5% | 6.71 | +11.2% | +14.6% | +3.6% | -2.2% | +1.2% | +12.1% | +36.1% | — |
| Aug 20, 2025 | AMC | 0.13 | -0.01 | -105.1% | 10.97 | +6.1% | +10.2% | +13.8% | +11.2% | +14.3% | +10.3% | -9.0% | — |
| Feb 20, 2025 | AMC | 0.09 | 0.07 | -25.2% | 17.41 | +9.9% | +12.0% | +20.2% | +12.0% | +10.3% | +8.6% | +4.8% | — |
| Aug 22, 2024 | AMC | 0.09 | 0.02 | -75.0% | — | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | AMC | — | 0.04 | — | — | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | 0.04 | -0.03 | -179.8% | — | — | — | — | — | — | — | — | — |
| Dec 31, 2022 | AMC | -0.05 | -0.07 | -45.5% | — | — | — | — | — | — | — | — | — |
| Jun 30, 2022 | AMC | -0.08 | -0.16 | -92.7% | — | — | — | — | — | — | — | — | — |
| Dec 31, 2021 | AMC | -0.05 | -0.12 | -126.6% | — | — | — | — | — | — | — | — | — |
| Jun 30, 2021 | AMC | — | -0.09 | — | — | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.54 | $11.03 | +4.6% | +6.6% | +1.5% | +1.1% | +1.9% | +1.9% |
| Apr 13 | Wedbush | Maintains | Outperform → Outperform | — | $10.54 | $11.03 | +4.6% | +6.6% | +1.5% | +1.1% | +1.9% | +1.9% |
| Apr 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.09 | $9.49 | +4.4% | +5.9% | +7.6% | +7.8% | +16.0% | +23.7% |
| Apr 7 | Wedbush | Maintains | Outperform → Outperform | — | $9.09 | $9.49 | +4.4% | +5.9% | +7.6% | +7.8% | +16.0% | +23.7% |
| Feb 24 | Citigroup | Maintains | Buy → Buy | — | $6.95 | $6.49 | -6.6% | -5.6% | -2.3% | +8.2% | +4.3% | +1.4% |
| Jan 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.73 | $7.36 | -4.8% | -5.4% | -1.4% | -1.6% | -1.0% | +8.2% |
| Dec 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.80 | $8.02 | +2.8% | +3.2% | +3.7% | +3.8% | +2.9% | +0.5% |
| Sep 23 | UBS | Maintains | Buy → Buy | — | $10.05 | $10.57 | +5.2% | +8.8% | +1.6% | +0.6% | -0.7% | -1.6% |
| Sep 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.29 | $9.54 | +2.7% | +4.3% | +0.3% | -0.9% | +2.4% | +1.4% |
| Aug 28 | JP Morgan | Downgrade | Overweight → Neutral | — | $12.10 | $10.01 | -17.3% | -16.1% | -21.1% | -22.1% | -22.6% | -25.0% |
Data updated apr 27, 2026 5:00am
· Source: massive.com